Compare · COGT vs JNJ
COGT vs JNJ
Side-by-side comparison of Cogent Biosciences Inc. (COGT) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COGT and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $643.64B, about 108.5x COGT ($5.93B).
- Over the past year, COGT is up 168.1% and JNJ is up 52.0% - COGT leads by 116.1 points.
- JNJ has been more active in the news (8 items in the past 4 weeks vs 3 for COGT).
- JNJ has more recent analyst coverage (25 ratings vs 17 for COGT).
- Company
- Cogent Biosciences Inc.
- Johnson & Johnson
- Price
- $34.14-3.22%
- $267.13-0.76%
- Market cap
- $5.93B
- $643.64B
- 1M return
- -17.75%
- +2.10%
- 1Y return
- +168.08%
- +51.96%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 3
- 8
- Recent ratings
- 17
- 25
Cogent Biosciences Inc.
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest COGT
- SEC Form 8-K filed by Cogent Biosciences Inc.
- Director Morris Arlene exercised 45,510 shares at a strike of $5.39 and sold $1,689,493 worth of shares (45,510 units at $37.12) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Cogent Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Cogent Biosciences Inc.
- SEC Form 8-K filed by Cogent Biosciences Inc.
- SEC Form 424B5 filed by Cogent Biosciences Inc.
- SEC Form 10-Q filed by Cogent Biosciences Inc.
- Cogent Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results
- SEC Form 4 filed by Director Ferrante Karen Jean
Latest JNJ
- Johnson & Johnson spotlights new neuropsychiatry data across bipolar mania, depression and schizophrenia at Psych Congress 2026
- EVP, WW Chair, MedTech Schmid Timothy exercised 33,597 shares at a strike of $144.99 and sold $9,230,440 worth of shares (33,597 units at $274.74) (SEC Form 4)
- Johnson & Johnson to Participate in the Deutsche Bank 2026 Healthcare Summit
- UBS resumed coverage on Johnson & Johnson with a new price target
- New insider Cavanaugh Thomas claimed ownership of 499 shares (SEC Form 3)
- Johnson & Johnson to Host Investor Conference Call on Third-Quarter Results
- FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients
- EVP, WWC. Innovative Medicine Taubert Jennifer L exercised 15,000 shares at a strike of $115.67 and sold $3,950,400 worth of shares (15,000 units at $263.36) (SEC Form 4)
- CEO and Chairman of the Board Duato Joaquin exercised 123,291 shares at a strike of $115.67 and sold $32,199,927 worth of shares (123,291 units at $261.17) (SEC Form 4)
- Johnson & Johnson to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference